Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Ovarian Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Adnexal Neoplasm
Female Reproductive System Adnexal Neoplasm
Ovarian Neoplasm

Subtype

Ovarian Neoplasm

CI-CAN-00001335Explore in graph →

Non-malignant746 active trials5 approved drugs94 evidence items

NCIt: C4984
MeSH: D010051

Overview
Statistics
Survival
Genomics9
Variants & evidence94
Drugs32
Trials3430
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (174)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–174 of 174 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed
Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.
· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed
Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed
Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.

Showing 151–174 of 174 publications

← Previous
1
…
6
7
Next →

· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

· Cancer Res · 2012 · PMID 22896685 · validated civic_curation pubmed

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

· Cancer Cell · 2015 · PMID 26096845 · validated civic_curation pubmed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

· Cancer Cell · 2010 · PMID 20227043 · validated civic_curation pubmed

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

· Cancer Res · 2015 · PMID 25968887 · validated civic_curation pubmed

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

· Clin Cancer Res · 2011 · PMID 21278246 · validated civic_curation pubmed

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

· Clin Cancer Res · 2011 · PMID 22016507 · validated civic_curation pubmed

Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.

· Oncol Rep · 2012 · PMID 22246397 · validated civic_curation pubmed

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.

· Int J Cancer · 2009 · PMID 19533750 · validated civic_curation pubmed

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.

· Nat Commun · 2025 · PMID 40169546 · validated civic_curation pubmed

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.

· Mol Cancer Ther · 2006 · PMID 17088436 · validated civic_curation pubmed

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

· Gynecol Oncol · 2005 · PMID 15790433 · validated civic_curation pubmed

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.

· Oncotarget · 2015 · PMID 26204491 · validated civic_curation pubmed

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

· Mol Oncol · 2013 · PMID 23415752 · validated civic_curation pubmed

Elkin et al. NPJ Genome Med 2021

· 2021 · PMID 34819508 · validated cbioportal_study pubmed

Manning-Geist et al. Clin Cancer Res. 2022

· 2022 · PMID 35443055 · validated cbioportal_study pubmed

TCGA, Nature 2011

· 2011 · PMID 21720365 · validated cbioportal_study pubmed